Cargando…

Effect of selenium supplementation on CD4(+) T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial

OBJECTIVE: To examine the effect of selenium supplementation on CD4(+) T-cell counts, viral suppression, and time to antiretroviral therapy (ART) initiation in ART-naive HIV-infected patients in Rwanda. METHODS: A multicenter, double-blinded, placebo-controlled, randomized clinical trial was conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamwesiga, Julius, Mutabazi, Vincent, Kayumba, Josephine, Tayari, Jean-Claude K., Uwimbabazi, Jean Claude, Batanage, Gad, Uwera, Grace, Baziruwiha, Marcel, Ntizimira, Christian, Murebwayire, Antoinette, Haguma, Jean Pierre, Nyiransabimana, Julienne, Nzabandora, Jean Bosco, Nzamwita, Pascal, Mukazayire, Ernestine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444428/
https://www.ncbi.nlm.nih.gov/pubmed/25870994
http://dx.doi.org/10.1097/QAD.0000000000000673
_version_ 1782373145491013632
author Kamwesiga, Julius
Mutabazi, Vincent
Kayumba, Josephine
Tayari, Jean-Claude K.
Uwimbabazi, Jean Claude
Batanage, Gad
Uwera, Grace
Baziruwiha, Marcel
Ntizimira, Christian
Murebwayire, Antoinette
Haguma, Jean Pierre
Nyiransabimana, Julienne
Nzabandora, Jean Bosco
Nzamwita, Pascal
Mukazayire, Ernestine
author_facet Kamwesiga, Julius
Mutabazi, Vincent
Kayumba, Josephine
Tayari, Jean-Claude K.
Uwimbabazi, Jean Claude
Batanage, Gad
Uwera, Grace
Baziruwiha, Marcel
Ntizimira, Christian
Murebwayire, Antoinette
Haguma, Jean Pierre
Nyiransabimana, Julienne
Nzabandora, Jean Bosco
Nzamwita, Pascal
Mukazayire, Ernestine
author_sort Kamwesiga, Julius
collection PubMed
description OBJECTIVE: To examine the effect of selenium supplementation on CD4(+) T-cell counts, viral suppression, and time to antiretroviral therapy (ART) initiation in ART-naive HIV-infected patients in Rwanda. METHODS: A multicenter, double-blinded, placebo-controlled, randomized clinical trial was conducted. Eligible patients were HIV-infected adults (≥21 years) who had a CD4(+) cell count between 400 and 650 cells/μl (ART eligibility was ≤350 cells/μl throughout the trial), and were willing to practice barrier methods of birth control. Patients were randomized to receive once-daily 200 μg selenium tablets or identical placebo. They were followed for 24 months with assessments every 6 months. Declines in CD4(+) cell counts were modeled using linear regressions with generalized estimating equations and effect modification, and the composite outcome (ART eligible or ART initiation) using Cox proportional-hazards regression, both conducted with intention to treat. RESULTS: Of the 300 participants, 149 received selenium, 202 (67%) were women, and median age was 33.5 years. The rate of CD4(+) depletion was reduced by 43.8% [95% confidence interval (CI) 7.8–79.8% decrease] in the treatment arm – from mean 3.97 cells/μl per month to mean 2.23 cells/μl per month. We observed 96 composite outcome events – 45 (47%) in the treatment arm. We found no treatment effect for the composite outcome (hazard ratio 1.00, 95% CI 0.66–1.54) or viral suppression (odds ratio 1.18, 95% CI 0.71–1.94). The trial was underpowered for the composite outcome due to a lower-than-anticipated event rate. Adverse events were comparable throughout. CONCLUSIONS: This randomized clinical trial demonstrated that 24-month selenium supplementation significantly reduces the rate of CD4(+) cell count decline among ART-naive patients.
format Online
Article
Text
id pubmed-4444428
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-44444282015-06-30 Effect of selenium supplementation on CD4(+) T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial Kamwesiga, Julius Mutabazi, Vincent Kayumba, Josephine Tayari, Jean-Claude K. Uwimbabazi, Jean Claude Batanage, Gad Uwera, Grace Baziruwiha, Marcel Ntizimira, Christian Murebwayire, Antoinette Haguma, Jean Pierre Nyiransabimana, Julienne Nzabandora, Jean Bosco Nzamwita, Pascal Mukazayire, Ernestine AIDS Clinical Science OBJECTIVE: To examine the effect of selenium supplementation on CD4(+) T-cell counts, viral suppression, and time to antiretroviral therapy (ART) initiation in ART-naive HIV-infected patients in Rwanda. METHODS: A multicenter, double-blinded, placebo-controlled, randomized clinical trial was conducted. Eligible patients were HIV-infected adults (≥21 years) who had a CD4(+) cell count between 400 and 650 cells/μl (ART eligibility was ≤350 cells/μl throughout the trial), and were willing to practice barrier methods of birth control. Patients were randomized to receive once-daily 200 μg selenium tablets or identical placebo. They were followed for 24 months with assessments every 6 months. Declines in CD4(+) cell counts were modeled using linear regressions with generalized estimating equations and effect modification, and the composite outcome (ART eligible or ART initiation) using Cox proportional-hazards regression, both conducted with intention to treat. RESULTS: Of the 300 participants, 149 received selenium, 202 (67%) were women, and median age was 33.5 years. The rate of CD4(+) depletion was reduced by 43.8% [95% confidence interval (CI) 7.8–79.8% decrease] in the treatment arm – from mean 3.97 cells/μl per month to mean 2.23 cells/μl per month. We observed 96 composite outcome events – 45 (47%) in the treatment arm. We found no treatment effect for the composite outcome (hazard ratio 1.00, 95% CI 0.66–1.54) or viral suppression (odds ratio 1.18, 95% CI 0.71–1.94). The trial was underpowered for the composite outcome due to a lower-than-anticipated event rate. Adverse events were comparable throughout. CONCLUSIONS: This randomized clinical trial demonstrated that 24-month selenium supplementation significantly reduces the rate of CD4(+) cell count decline among ART-naive patients. Lippincott Williams & Wilkins 2015-06-01 2015-05-20 /pmc/articles/PMC4444428/ /pubmed/25870994 http://dx.doi.org/10.1097/QAD.0000000000000673 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Clinical Science
Kamwesiga, Julius
Mutabazi, Vincent
Kayumba, Josephine
Tayari, Jean-Claude K.
Uwimbabazi, Jean Claude
Batanage, Gad
Uwera, Grace
Baziruwiha, Marcel
Ntizimira, Christian
Murebwayire, Antoinette
Haguma, Jean Pierre
Nyiransabimana, Julienne
Nzabandora, Jean Bosco
Nzamwita, Pascal
Mukazayire, Ernestine
Effect of selenium supplementation on CD4(+) T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial
title Effect of selenium supplementation on CD4(+) T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial
title_full Effect of selenium supplementation on CD4(+) T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial
title_fullStr Effect of selenium supplementation on CD4(+) T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial
title_full_unstemmed Effect of selenium supplementation on CD4(+) T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial
title_short Effect of selenium supplementation on CD4(+) T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial
title_sort effect of selenium supplementation on cd4(+) t-cell recovery, viral suppression and morbidity of hiv-infected patients in rwanda: a randomized controlled trial
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444428/
https://www.ncbi.nlm.nih.gov/pubmed/25870994
http://dx.doi.org/10.1097/QAD.0000000000000673
work_keys_str_mv AT kamwesigajulius effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT mutabazivincent effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT kayumbajosephine effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT tayarijeanclaudek effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT uwimbabazijeanclaude effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT batanagegad effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT uweragrace effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT baziruwihamarcel effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT ntizimirachristian effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT murebwayireantoinette effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT hagumajeanpierre effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT nyiransabimanajulienne effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT nzabandorajeanbosco effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT nzamwitapascal effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial
AT mukazayireernestine effectofseleniumsupplementationoncd4tcellrecoveryviralsuppressionandmorbidityofhivinfectedpatientsinrwandaarandomizedcontrolledtrial